Patterns of FGF-23, DMP1, and MEPE expression in patients with chronic kidney disease.
about
Phosphate and FGF-23The amazing osteocyteFibroblast growth factor 23Bone disease in pediatric chronic kidney diseaseFibroblast Growth Factor 23: A New Dimension to Diseases of Calcium-Phosphorus MetabolismDysregulated gene expression in the primary osteoblasts and osteocytes isolated from hypophosphatemic Hyp miceRelationship between Fibroblast Growth Factor 23 and Biochemical and Bone Histomorphometric Alterations in a Chronic Kidney Disease Rat Model Undergoing ParathyroidectomyA link between central kynurenine metabolism and bone strength in rats with chronic kidney disease.Expression of fibroblast growth factor 23, vitamin D receptor, and sclerostin in bone tissue from hypercalciuric stone formers.The use of fibroblast growth factor 23 testing in patients with kidney disease.CKD-induced wingless/integration1 inhibitors and phosphorus cause the CKD-mineral and bone disorder.FGF23 protein expression in coronary arteries is associated with impaired kidney function.The phosphatonin fibroblast growth factor 23 links calcium-phosphate metabolism with left-ventricular dysfunction and atrial fibrillation.FGF23 is a novel regulator of intracellular calcium and cardiac contractility in addition to cardiac hypertrophy.Fibroblast growth factor 23 in acute kidney injury.Chronic kidney disease: mineral and bone disorder in children.Fibroblast growth factor-23 and calcium phosphate product in young chronic kidney disease patients: a cross-sectional studyMarkers of bone metabolism are affected by renal function and growth hormone therapy in children with chronic kidney disease.Coupling fibroblast growth factor 23 production and cleavage: iron deficiency, rickets, and kidney disease.Primary osteoblast-like cells from patients with end-stage kidney disease reflect gene expression, proliferation, and mineralization characteristics ex vivo.FGF-23: More than a regulator of renal phosphate handling?Long-term clinical outcome and carrier phenotype in autosomal recessive hypophosphatemia caused by a novel DMP1 mutation.Osteocytic protein expression response to doxercalciferol therapy in pediatric dialysis patients.Cell line IDG-SW3 replicates osteoblast-to-late-osteocyte differentiation in vitro and accelerates bone formation in vivo.Fibroblast growth factor 23 in patients undergoing peritoneal dialysisMineral abnormalities and long-term graft function in pediatric renal transplant recipients: a role for FGF-23?Early skeletal and biochemical alterations in pediatric chronic kidney disease.Altered Osteocyte-Specific Protein Expression in Bone after Childhood Solid Organ Transplantation.FGF-23 serum levels and bone histomorphometric results in adult patients with chronic kidney disease on dialysisUpdate on fibroblast growth factor 23 in chronic kidney disease.Pathophysiology of the chronic kidney disease-mineral bone disorder.FGF-23 and the progression of coronary arterial calcification in patients new to dialysis.Plasma FGF23 and Calcified Atherosclerotic Plaque in African Americans with Type 2 Diabetes Mellitus.FGF23 production by osteocytes.Oncogenic osteomalacia due to FGF23-expressing colon adenocarcinomaMicro-CT in the Assessment of Pediatric Renal Osteodystrophy by Bone Histomorphometry.Fibroblast growth factor 23 and bone mineralisation.Sclerostin alters serum vitamin D metabolite and fibroblast growth factor 23 concentrations and the urinary excretion of calciumForum on aging and skeletal health: summary of the proceedings of an ASBMR workshopIdiopathic juvenile osteoporosis: a cross-sectional single-centre experience with bone histomorphometry and quantitative computed tomography.
P2860
Q24610674-2D5414FD-DAC0-41ED-A40C-868285375B25Q24635849-196756EE-2850-4A41-8B55-71B4EF5BCDD4Q26829294-9CCC535A-0B87-426A-8696-283BB2F24146Q26864102-F704ABFE-49E5-48AC-8203-F20DD2A1BC14Q26866263-066FAE48-83F3-4C06-8DB4-BE399190F5EBQ27345068-1EE3C080-0303-46EA-96FA-23776685318AQ28546638-2BB11BF0-50F3-41C1-96A6-6D4400FB61ACQ33592717-4328C740-ACB0-4F72-8E1A-28B72A98C13DQ33835734-E8ABECE8-C4C2-41B0-9D2C-55959BB15991Q33835743-69DB5C30-4017-4229-8CF3-A868CFF9528FQ33974636-4A2E5C53-53EC-4BA5-B73B-01433E45B88FQ33985430-2AE04CE7-EE3F-45E2-B29B-14EEBB4DBB2CQ34027561-E5DE48FB-646B-4D7B-947B-E74C5ACE3D09Q34035797-E93B192C-3E2B-4151-9E0D-62F2FBC20D96Q34280125-7D3142CC-241E-4992-B7D7-0860357F15C0Q34402661-5EFBBE01-352C-41AE-88B2-727F935BB627Q34588377-D5B909BD-27A2-40EF-87B9-8C7C9CFD1B82Q35058295-4BAEFF78-2219-4EDF-A5B6-E494DD422428Q35067500-BF5AD10E-8AD9-46C0-B948-19168BC057F4Q35132542-AAF538E1-5D32-42A3-98CB-9136B952A972Q35156017-0AADA961-B90E-4AFA-A3F0-C7505E01FEE5Q35156029-A50B4F00-6D96-4A6B-B0CA-7B47400F94DAQ35182281-7003F335-F667-42EE-9D43-CD909A2D6D28Q35332147-C43F5780-1BC2-4838-A233-BCD739B68567Q35499669-D7325B5A-9E14-4228-BAB7-FA17FD48DAC1Q35639150-242AA245-A9AD-4802-9202-ACDEBE9B8CB8Q35692418-A8FA5463-863C-4348-872F-24CB73641058Q35782011-61211C3D-6B99-479B-AA2E-1618D324E6AAQ35949319-57AD5C75-EE0A-4769-891A-7172DA6B3A9AQ36210285-DD66DA77-5AAD-44D7-A849-0749910109E7Q36425115-8B4B3D0F-0E86-4A44-9623-6D017098DC1CQ36443208-326C691F-CF26-4053-AD35-DE47AC94D350Q36520483-A1D3ED44-3F9E-4AB9-B23C-4728D124299BQ36639867-AB2A616D-2B2C-4958-B4AD-49EAE6E01C75Q36663069-66BCED1E-F87F-4A08-B7D1-12391A72CCF5Q36686979-1106A4A8-94C5-4777-9183-C89517389D5DQ36756061-652AD40C-2EE2-4F74-8543-AD525D962F16Q36762750-1D5436D2-20DC-4C17-AB3B-94273327E9CCQ36763014-5C4D6CD0-5157-4279-86B8-01BBA1B0A498Q36805265-A574206D-5370-48DB-851E-4B625930DAFA
P2860
Patterns of FGF-23, DMP1, and MEPE expression in patients with chronic kidney disease.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 11 August 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Patterns of FGF-23, DMP1, and MEPE expression in patients with chronic kidney disease.
@en
Patterns of FGF-23, DMP1, and MEPE expression in patients with chronic kidney disease.
@nl
type
label
Patterns of FGF-23, DMP1, and MEPE expression in patients with chronic kidney disease.
@en
Patterns of FGF-23, DMP1, and MEPE expression in patients with chronic kidney disease.
@nl
prefLabel
Patterns of FGF-23, DMP1, and MEPE expression in patients with chronic kidney disease.
@en
Patterns of FGF-23, DMP1, and MEPE expression in patients with chronic kidney disease.
@nl
P2093
P2860
P1433
P1476
Patterns of FGF-23, DMP1, and MEPE expression in patients with chronic kidney disease.
@en
P2093
Carlos E Azucena-Serrano
Harald Juppner
Isidro B Salusky
Katherine Wesseling-Perry
Renata C Pereira
P2860
P304
P356
10.1016/J.BONE.2009.08.008
P577
2009-08-11T00:00:00Z